JP2017530959A - Ｃａｒｍ１阻害剤およびその使用 - Google Patents
Ｃａｒｍ１阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2017530959A JP2017530959A JP2017514627A JP2017514627A JP2017530959A JP 2017530959 A JP2017530959 A JP 2017530959A JP 2017514627 A JP2017514627 A JP 2017514627A JP 2017514627 A JP2017514627 A JP 2017514627A JP 2017530959 A JP2017530959 A JP 2017530959A
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- formula
- ring
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC=CCCC(C1)CN1C(*)=O Chemical compound CC=CCCC(C1)CN1C(*)=O 0.000 description 14
- GASDEPVDZRWESS-UHFFFAOYSA-N CC(C)(C)NC(CC1)CCN1C(OC)=O Chemical compound CC(C)(C)NC(CC1)CCN1C(OC)=O GASDEPVDZRWESS-UHFFFAOYSA-N 0.000 description 1
- AHDXITUHQUXWNX-UHFFFAOYSA-N CC(C)(CN(C1)c2c(C)c(NC3CCOCC3)nc(-c3cc(OCC(CNC)O)ccc3)n2)NC1[O](CC1)CCC1Nc1nc(-c2cc(OCC(CNC)O)ccc2)nc(N(CC2)CCN2C2CC2)c1C Chemical compound CC(C)(CN(C1)c2c(C)c(NC3CCOCC3)nc(-c3cc(OCC(CNC)O)ccc3)n2)NC1[O](CC1)CCC1Nc1nc(-c2cc(OCC(CNC)O)ccc2)nc(N(CC2)CCN2C2CC2)c1C AHDXITUHQUXWNX-UHFFFAOYSA-N 0.000 description 1
- CREMVSNTSMCKGG-UHFFFAOYSA-N CN(C1)Cc2c1nccn2 Chemical compound CN(C1)Cc2c1nccn2 CREMVSNTSMCKGG-UHFFFAOYSA-N 0.000 description 1
- NFUXMHAMVXNKGQ-UHFFFAOYSA-N CNCC(COc1cc(Cl)cc(-c2nc(-c3ccncc3)cc(N3CCOCC3)n2)c1)O Chemical compound CNCC(COc1cc(Cl)cc(-c2nc(-c3ccncc3)cc(N3CCOCC3)n2)c1)O NFUXMHAMVXNKGQ-UHFFFAOYSA-N 0.000 description 1
- LRCHULLHPXIBOK-UHFFFAOYSA-N CNCC(COc1cccc(-c2nc(-c3c(C(C4)NCCC4Nc4nc(-c5cc(Cl)cc(OCC(CNC)O)c5)nc(-c5ccncc5)c4)cncc3)cc(NC3CCNCC3)n2)c1)O Chemical compound CNCC(COc1cccc(-c2nc(-c3c(C(C4)NCCC4Nc4nc(-c5cc(Cl)cc(OCC(CNC)O)c5)nc(-c5ccncc5)c4)cncc3)cc(NC3CCNCC3)n2)c1)O LRCHULLHPXIBOK-UHFFFAOYSA-N 0.000 description 1
- MZKPQJPRNDBCGB-UHFFFAOYSA-N CNCC(COc1cccc(-c2nc(-c3cc(C#N)ccc3)cc(N(CCOC)CCOC)n2)c1)O Chemical compound CNCC(COc1cccc(-c2nc(-c3cc(C#N)ccc3)cc(N(CCOC)CCOC)n2)c1)O MZKPQJPRNDBCGB-UHFFFAOYSA-N 0.000 description 1
- FCDQVRGVMYUYQG-UHFFFAOYSA-N CNCC(COc1cccc(-c2nc(C3=CC=C[IH]C=C3)cc(NCC3CCNCC3)n2)c1)O Chemical compound CNCC(COc1cccc(-c2nc(C3=CC=C[IH]C=C3)cc(NCC3CCNCC3)n2)c1)O FCDQVRGVMYUYQG-UHFFFAOYSA-N 0.000 description 1
- NQUFVLNJQPBCNO-CLFYSBASSA-N CO/C(/C(CC1)CCN1C(OC)=O)=C\S Chemical compound CO/C(/C(CC1)CCN1C(OC)=O)=C\S NQUFVLNJQPBCNO-CLFYSBASSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051872P | 2014-09-17 | 2014-09-17 | |
| US62/051,872 | 2014-09-17 | ||
| PCT/US2015/050712 WO2016044604A1 (en) | 2014-09-17 | 2015-09-17 | Carm1 inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530959A true JP2017530959A (ja) | 2017-10-19 |
| JP2017530959A5 JP2017530959A5 (cg-RX-API-DMAC7.html) | 2018-11-01 |
Family
ID=55533856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514627A Withdrawn JP2017530959A (ja) | 2014-09-17 | 2015-09-17 | Ｃａｒｍ１阻害剤およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170305922A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3193608A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017530959A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016044604A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021532157A (ja) * | 2018-08-01 | 2021-11-25 | アラクセス ファーマ エルエルシー | がんを処置するための複素環式スピロ化合物およびその使用方法 |
| JP2023518396A (ja) * | 2020-03-18 | 2023-05-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｃａｒｍ１の阻害によるがん治療法 |
| US12234244B2 (en) | 2013-10-10 | 2025-02-25 | Araxes Pharma Llc | Substituted piperazines as inhibitors of KRAS G12C |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE040323T2 (hu) | 2012-12-21 | 2019-02-28 | Epizyme Inc | PRMT5-inhibitorok és alkalmazásaik |
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP2016505001A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| EP2935243B1 (en) | 2012-12-21 | 2018-03-14 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| AU2014236146B2 (en) | 2013-03-14 | 2018-05-17 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970137A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| CN105228997B (zh) | 2013-03-15 | 2018-03-27 | Epizyme股份有限公司 | Carm1抑制剂及其用途 |
| JP2017530940A (ja) | 2014-08-04 | 2017-10-19 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| LT3394033T (lt) | 2015-12-22 | 2021-03-10 | Incyte Corporation | Heterocikliniai junginiai, kaip imunomoduliatoriai |
| US20170320875A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HRP20221030T1 (hr) | 2016-06-20 | 2022-11-11 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| CA3042700A1 (en) | 2016-11-07 | 2018-05-11 | University Of Massachusetts | Therapeutic targets for facioscapulohumeral muscular dystrophy |
| JP7149276B2 (ja) | 2016-12-22 | 2022-10-06 | インサイト・コーポレイション | Ｐｄ－ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５－ｃ］ピリジン誘導体 |
| BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corporation | derivados de benzo-oxazol como imunomoduladores |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| ES2788856T3 (es) | 2017-03-20 | 2020-10-23 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| MX2019013954A (es) | 2017-05-25 | 2020-08-31 | Araxes Pharma Llc | Inhibidores covalentes de kras. |
| JP2020521740A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体 |
| MY210070A (en) | 2018-03-30 | 2025-08-25 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| PT3790877T (pt) | 2018-05-11 | 2023-05-10 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1 |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| CA3144344A1 (en) | 2019-06-28 | 2020-12-30 | Als Therapy Development Institute | Inhibition of dipeptide repeat proteins |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| MA57202B1 (fr) | 2019-09-19 | 2025-09-30 | Novo Nordisk Health Care Ag | Compositions d'activation de la pyruvate kinase r (pkr) |
| BR112022005826A2 (pt) | 2019-09-30 | 2022-06-21 | Incyte Corp | Compostos de pirido[3,2-d]pirimidina como imunomoduladores |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004886D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2008104077A1 (en) * | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| WO2010028179A1 (en) * | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
| CA2894157A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN105228997B (zh) * | 2013-03-15 | 2018-03-27 | Epizyme股份有限公司 | Carm1抑制剂及其用途 |
| WO2016044641A2 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
-
2015
- 2015-09-17 JP JP2017514627A patent/JP2017530959A/ja not_active Withdrawn
- 2015-09-17 US US15/511,503 patent/US20170305922A1/en not_active Abandoned
- 2015-09-17 EP EP15842456.4A patent/EP3193608A4/en not_active Withdrawn
- 2015-09-17 WO PCT/US2015/050712 patent/WO2016044604A1/en not_active Ceased
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12234244B2 (en) | 2013-10-10 | 2025-02-25 | Araxes Pharma Llc | Substituted piperazines as inhibitors of KRAS G12C |
| JP2021532157A (ja) * | 2018-08-01 | 2021-11-25 | アラクセス ファーマ エルエルシー | がんを処置するための複素環式スピロ化合物およびその使用方法 |
| JP2024149542A (ja) * | 2018-08-01 | 2024-10-18 | アラクセス ファーマ エルエルシー | がんを処置するための複素環式スピロ化合物およびその使用方法 |
| JP2023518396A (ja) * | 2020-03-18 | 2023-05-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｃａｒｍ１の阻害によるがん治療法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170305922A1 (en) | 2017-10-26 |
| EP3193608A1 (en) | 2017-07-26 |
| WO2016044604A1 (en) | 2016-03-24 |
| EP3193608A4 (en) | 2018-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530959A (ja) | Ｃａｒｍ１阻害剤およびその使用 | |
| CN105228997B (zh) | Carm1抑制剂及其用途 | |
| CN104144926B (zh) | 噁唑烷-2-酮化合物及其作为磷脂酰肌醇-3-激酶抑制剂的用途 | |
| KR20250057919A (ko) | PI3Kα 억제제 및 이의 사용 방법 | |
| KR20180015255A (ko) | Hpk1 억제제 및 이의 사용 방법 | |
| JP2019527217A (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 | |
| TW201404779A (zh) | 新的雜芳基和雜環化合物、其組合物及方法 | |
| SG193513A1 (en) | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases | |
| WO2007037534A1 (ja) | ２－へテロアリール置換インドール誘導体 | |
| US10174040B2 (en) | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | |
| EP4370124A1 (en) | PI3Ka INHIBITORS AND METHODS OF USE THEREOF | |
| JPWO2017111074A1 (ja) | ピロロピリミジン化合物による抗腫瘍効果増強剤 | |
| CN107074805A (zh) | 用于治疗疾病的gls1抑制剂 | |
| US20250230138A1 (en) | Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications | |
| JP2017534663A (ja) | サーチュイン調節因子としての置換架橋尿素類似体 | |
| US20240368183A1 (en) | Macrocyclic Compounds Having ENT1 Inhibiting Activity | |
| CN115873000B (zh) | 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途 | |
| US20240368122A1 (en) | Jak2 inhibitors and methods of use thereof | |
| US20190135793A1 (en) | Heterocyclic inhibitors of kdm5 for the treatment of disease | |
| CN104640862B (zh) | 新的杂芳基和杂环化合物、其组合物及方法 | |
| US12240830B2 (en) | Fused ring heteroaryl compounds and use thereof | |
| US11660303B2 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | |
| WO2023109540A1 (zh) | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 | |
| CN116514817A (zh) | 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途 | |
| HK1255833B (en) | Hpk1 inhibitors and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170627 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170710 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20171220 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20171225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180914 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180914 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20181217 |